New drug for the treatment of exocrine pancreatic insufficiency

http://markets.businessinsider.com/news/stocks/AzurRx-BioPharma-and-Mayoly-Spindler-Announce-MS1819-SD-Investigational-Medicinal-Product-Dossier-IMPD-Submission-1005030890

AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) Submission

AzurRx BioPharma Inc. (NASDAQ:AZRX) (“AzurRx” or the Continue reading New drug for the treatment of exocrine pancreatic insufficiency

My Wish List for the New Year By Gunnar Esiason

I’m not naïve enough to think that I’m going to wake up tomorrow and find that my life is moving forward with cystic fibrosis in the rearview mirror.

We’re still a little bit away from that moment, but that doesn’t mean I don’t have high expectations for treatment development. Continue reading My Wish List for the New Year By Gunnar Esiason

AbbVie CF Scholarship Now Accepting Applications from Students with Cystic Fibrosis for 2016-2017 Academic School Year

Scholarship recognizes 40 exceptional students with cystic fibrosis (CF) for academic excellence, creativity, and community service

¾  More than $2.6 million in scholarships awarded over 24 year history of the program

 NORTH CHICAGO, Ill., April 6, 2016 – AbbVie (NYSE:ABBV) today announced that the 2016 AbbVie CF Scholarship, which honors and Continue reading AbbVie CF Scholarship Now Accepting Applications from Students with Cystic Fibrosis for 2016-2017 Academic School Year

Alcresta Pharmaceuticals Receives FDA Clearance for RELiZORB™

Alcresta Pharmaceuticals, a specialty pharmaceutical company focused on developing innovative enzyme-based products for gastrointestinal and rare disease, today announced it received de novo approval from the U.S. Food Continue reading Alcresta Pharmaceuticals Receives FDA Clearance for RELiZORB™

Anthera Announces Initiation of the SOLUTION Clinical Study of Oral Sollpura(R) (liprotamase) Unit-Matched Therapy of Non-Porcine Origin in People With Cystic Fibrosis

• Study to enroll approximately 130 patients with exocrine pancreatic insufficiency
• More than 50 clinical sites around the United States and Europe are expected to participate
• Anthera to host reception at the North American Cystic Fibrosis Conference to discuss the SOLUTION program. Continue reading Anthera Announces Initiation of the SOLUTION Clinical Study of Oral Sollpura(R) (liprotamase) Unit-Matched Therapy of Non-Porcine Origin in People With Cystic Fibrosis

A Unique Approach to the Treatment of EPI in Cystic Fibrosis

Of all the pancreatic enzyme medicines doctors can prescribe, PERTZYE®(pancrelipase) is the only choice that contains pancreatic enzymes buffered with bicarbonate.* Bicarbonate is a substance normally secreted along with pancreatic enzymes that helps them work efficiently to digest food. Continue reading A Unique Approach to the Treatment of EPI in Cystic Fibrosis

Cystic Fibrosis ‘Life Hacks’ by Gunnar Esiason

Before we get going here, I have to give a nod to a buddy of mine from BC, Matt Paré, for giving me the idea to write this one. Matt is a minor league ball player and has a blog at http://homelessminorleaguer.com/. He just did a “Life Hacks for Minor League Baseball Players” Continue reading Cystic Fibrosis ‘Life Hacks’ by Gunnar Esiason

Anthera, Patheon to Co-Manufacture Sollpura for CF Phase 3 Trial

Anthera Pharmaceuticals, Inc., a biopharmaceutical company that specializes in research and development of novel treatments for serious and fatal diseases such as lupus, lupus with nephrotic affectation, and exocrine pancreatic insufficiency (EPI) secondary to cystic fibrosis Continue reading Anthera, Patheon to Co-Manufacture Sollpura for CF Phase 3 Trial